埃托里可西布及其隐藏的风险:基于皮肤病,血液病和心血管并发症的个案审查
Mohamamd Anas Ansari1, Arun Kumar1
1School of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, India.
EXCLI journal
|November 12, 2025
概括
埃托里可西布可以引起罕见但严重的不良药物反应,包括皮肤反应,如史蒂文斯-约翰逊综合征 (SJS) 和心血管事件. 及时识别和停止治疗对于患者的安全至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 药品安全 药品安全
背景情况:
- 埃托里可西布是一种选择性COX-2抑制剂,用于治疗疼痛和炎症.
- 药物不良反应 (ADRs),特别是严重的过敏和心血管事件,与使用埃托里科克西布有关.
- 了解这些罕见但严重的副作用对于患者的安全至关重要.
研究的目的:
- 审查和整合与乙托利克西布相关的副作用的病例报告.
- 评估这些反应的因果关系,临床表现和安全影响.
- 突出严重过敏和心血管事件的风险.
主要方法:
- 对Etoricoxib诱导的副作用的病例报告的系统审查.
- 使用纳兰乔尺度和WHO-UMC标准对因果关系的分析.
- 巩固临床证据的呈现和结果.
主要成果:
- 埃托里可西布与严重的皮肤反应 (SJS,TEN,FDE,AGEP),血液问题 (TP,IHA) 和心血管事件 (高血压,AFib) 有关.
- 反应可以在开始治疗后的几个小时到几周内表现出来.
- 因果关系评估经常表明,埃托里科克西布与这些副作用之间可能存在联系.
结论:
- 埃托里科西布与罕见但严重的副作用有关,包括严重的皮肤反应和心血管问题.
- 仔细评估患者病史,并在怀疑时立即停止治疗至关重要.
- 需要加强药物监测,以更好地描述这些事件.
相关概念视频
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Therapeutic Drug Monitoring: Overview and Classification
282
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
282
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Therapeutic Drug Monitoring: Affecting Factors
189
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
189
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


